"name","description","rationale","uuid:ID","id","instanceType","label"
"Study Design 1","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","9c951072-43f3-4112-a6c5-c2e0930c82c4","StudyDesign_1","StudyDesign",""
